Compared to hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, TNBC is often diagnosed in younger women and has higher rates of distant recurrence within 2–3 years of diagnosis3,4. This evidence concerns the gene ERBB2 and breast cancer.